title: Of timing and surrogates: a way forward for cancer chemoprevention.
abstract: Cancer chemoprevention strategies are not widely implemented in clinical practice. Targeting biomarkers in patients with elevated risk of developing cancer by means of short-term administration of certain agents may be a strategy to minimize toxicities while maintaining efficacy in clinical trials that can be completed in years rather than decades.
authors.affiliation: Department of Cell and Molecular Medicine, Arizona Cancer Center, and BIO5 Institute, University of Arizona, Tucson,AZ 85724, USA. pthompson@azcc.arizona.edu
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Thompson
authors.forename: Eugene W
authors.initials: EW
authors.lastname: Gerner
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors; D000068579:Celecoxib; D018890:Chemoprevention; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013467:Sulindac / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D015415:Biomarkers; D014408:Biomarkers, Tumor; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D013467:Sulindac; D000068579:Celecoxib